Medicare Part D
Top in cardiology: Heart disease remains leading cause of death; low-value aspirin use
The American Heart Association has issued its heart disease and stroke statistical update for 2025, which provides an overview of statistics related to CVD, stroke and CV risk factors.
Cardiometabolic drugs consume majority of cost among those up for price negotiation
Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications consumed more than 80% of Medicare Part D spending, researchers reported.
Top in endocrinology: New criteria for diagnosing obesity; Medicare price negotiations
A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, including measuring body fat to diagnose obesity instead of BMI alone.
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
Inflation Reduction Act saves patients with cancer thousands in out-of-pocket spending
The Inflation Reduction Act’s cap on out-of-pocket spending saved patients with cancer more than $7,000 a year on oral chemotherapy medications, a research letter analysis published in JAMA Network Open showed.
Medicare to cover semaglutide for CV prevention for adults with overweight and obesity
Medicare Part D plans can begin to cover semaglutide to lower risk for cardiovascular events among adults with overweight or obesity and preexisting CVD, according to new guidance from the Centers of Medicare & Medicaid Services.
First 10 drugs chosen for Medicare price negotiations
HHS announced the first 10 drugs that will be subject to Medicare price negotiations.
Mark Cuban company could yield savings on seven Medicare generic oncology drugs
Mark Cuban Cost Plus Drug Company’s pricing could yield significant savings for seven generic oncology drugs vs. Medicare Part D median formulary prices, according to study results published in Journal of Clinical Oncology.
Insulin underuse due to costs remains high in primary care settings
In a recent survey, nearly half of primary care patients with type 1 or type 2 diabetes reported suboptimal insulin use due to costs.
ADA, Endocrine Society join President Biden in calling for insulin copay cap
Two major professional endocrinology organizations are calling on Congress to pass legislation capping out-of-pocket insulin costs for Americans with diabetes, according to two press releases.